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Unlocking the
Knowledge
The key to delivering the compliance and business benefits
outlined in ICH Q10
Nuala Calnan
PhD Researcher
Pharmaceutical Science & Regulatory Team (PSRT)
School of Chemical & Pharmaceutical Sciences
Dublin Institute of Technology
Ireland
Agenda
• Introduction to the Research program
• Overview of the Regulatory Drivers
• Review of Recent Regulatory Actions
• Challenges of delivering a holistic approach to the
Pharmaceutical Quality System (Q10) expectations
• Review of key relevant findings of recent ‘Operational
Excellence in the Pharmaceutical Industry’ St. Gallen Uni.
benchmarking report
• Knowledge is the Key
• How can we utilise familiar OPEX, Lean/ Six Sigma tools to
capture this knowledge and deliver the expectations and
opportunities for ICH Q10
George Nelson ball clock
PSRT Research Program
Aim: The purpose of this research is to develop a
science and risk based methodology for use by the
Pharmaceutical Industry which will provide a
practical integrated knowledge framework for
achieving, maintaining and facilitating continual
improvement of the ‘State of Control’ across the
entire lifecycle relating to the commercial
manufacture of human drug products.
An associated implementation toolset based on
lean/six sigma principles will also be developed
What were the key regulatory
strategies in use in your organisation at
that time?
Was your organization introducing new
products into your manufacturing
facilities ?
Preparing for a regulatory inspection?
Perhaps even busy responding to
regulatory observations or
actions following a recent inspection
or audit?
Where were you in July 2003 ?
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Quality: A New Paradigm*
In July 2003, at an
important ICH meeting in
Brussels, a new quality
vision was agreed on. This
emphasized a risk and
science-based approach to
pharmaceuticals in an
adequately implemented
quality system.
*This vision was referred to by Jean Louis Robert (ICH Q-IWG Rapporteur) as ‘Quality: A New Paradigm’ in the Integrated Implementation Training Workshop materials delivered in
Washington DC in November 2010.
Nov 2005 & Nov 2008
Source: ICH, November 2010
ICH Q10  Pharmaceutical Quality System
GMP
Pharmaceutical
Development
Commercial
Manufacturing Discontinuation
Technology
Transfer
Investigational products
Management Responsibilities
Process Performance & Product Quality Monitoring System
Corrective Action / Preventive Action  (CAPA) System
Change Management System
Management Review
PQS
elements
Knowledge Management
Quality Risk Management
Enablers
ICH Q10 PQS – Regulatory Context
Take note…
• Much of the content of ICH Q10 applicable to manufacturing sites is
currently specified by regional GMP requirements.
• ICH Q10 is not intended to create any new expectations beyond current
regulatory requirements.
• Consequently, the content of ICH Q10 that is additional to current regional
GMP requirements is optional.
However,
• ICH Q10 demonstrates industry and regulatory authorities’ support of an
effective pharmaceutical quality system to enhance the quality and
availability of medicines around the world in the interest of public health.
• Implementation of ICH Q10 throughout the product lifecycle should
facilitate innovation and continual improvement and strengthen the link
between pharmaceutical development and manufacturing activities
Recent Regulatory Action example 1
FDA Warning Letter to a Danish
Firm dated 2nd May 2012
Failure to establish and maintain adequate
procedures for validating the device
design. Design validation shall include risk
analysis, where appropriate, as required by
21 CFR 820.30(g).
For example, your firm’s procedure, (b)(4),
dated 01/10/2011, does not include or refer
to the process to be used when conducting a
risk analysis. ...... your firm did not establish
a process for identifying the potential
hazards of the design project as required by
the standard being used (b)(4).
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Recent Regulatory Action example 2
FDA Warning Letter to a Spanish
Firm dated 24th April 2012
3. Your firm has not established scientifically
sound and appropriate specifications,
standards, sampling plans, and test
procedures designed to assure that
drug products conform to appropriate
standards of identity, strength,
quality, and purity [21 C.F.R. § 211.160(b)].
Warning Letter OTC Manufacturer
• Firm’s management, including the Quality Control
Unit, was not responsive to adverse trend of
customer complaints.
• Failure of your Quality Control Unit to ensure a
thorough investigation with conclusions and follow up
accomplished (two deviations, both 211.192 and
211.198)
• Senior management (includes corporate in this case)
is responsible for ensuring the quality, safety, and
integrity of your firm’s drug products.
Recent Regulatory Action example 3
FDA Warning Letter to a US OTC
Manufacturer dated….2011
Source: CDER Update University of Georgia GMP Conference March 15-17, 2011, Richard L. Friedman, Director, Division of Manufacturing and Product Quality, Office of Compliance
FDA/CDER
Challenges to Holistic Implementation of QbD Principles St.Gallen University OPEX Benchmarking
Industry Pharmaceutical
Number of
Production Sites
181 (Total)
? 134 (Formulation & Packaging)
? 38 (API)
? 9 (Biotech)
Number of
Companies
91 (Total)including ten companies of the Top20*
Content – Scope Enabler Implementation andPerformance Metrics (KPIs)
Content – Modules Total Productive Maintenance (TPM)Total Quality Management (TQM)Just-in-Time (JIT)Effective Management SystemStatus: November 2011 *according to Pharmaceutical Executive
Published 2010,
Operations Management  COP
Foreword written by ISPE
Source: Mastering Plant Complexity and the Impact of Operational Excellence, Prof. Dr. Thomas Friedli,  University of St.Gallen, OPEX-Benchmarking
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How to achieve Excellence?
Excellence deals with doing the right things (quality, delivery) and
doing things right (efficiency, costs)
Measure and control the whole picture! Stabilize first, reduce waste second!1 2
… … …
Capacity and TechnologyManagement
Total ProductiveMaintenance Quality and ProcessManagement
Total QualityManagement Materials and OperationsManagementJust-In-Time
Preventive Maintenance
? Integration of operators?
? Prefer external or internalmaintenance?
Technology Assessment and
Usage
? Role of leading edgetechnology?
? Equipment is protected bypatent?
Housekeeping
? Cleaning by operators?
Process Management
? Statistical process control andprocess quality?
? Role of PAT implementation
Customer Integration
? Collaboration with R&D toaccelerate scale-ups?
? Standardized procedures forprocess and product transfer?
Supplier Quality Management
? Joint initiatives?
? Feedback survey?
Planning Adherence
? Smoothly leveled productionor high level of capacityutilization?
Pull Production
? Make-to-forecast or make-to-order?
? Kanban systems?
Layout Optimization
? Design by product groups?
? Tact time, continuous flow?
Setup Time Reduction
? Priority of setup timereduction?
OEE (API)
Lowest 10% 60,5%
Top Performer 95,0%
Average Sample 71,6%
Forecast Accuracy
Lowest 10% 61,5%
Top Performer 95,0%
Average Sample 73,2%
Functional Integration
Lowest 10% 32,9%
Top Performer 85,0%
Average Sample 51,0%
Source: Mastering Plant Complexity and the Impact of Operational Excellence, Prof. Dr. Thomas Friedli,  University of St.Gallen, OPEX-Benchmarking
What does Top Performance mean for TQM?
? A Top Performer has a
higher yield and a
comparable low cost of
quality
? The Top 10% of our
sample have a
QA&QC/direct-
Employees-ratio of  22%
compared to this Top
Performer´s ratio of 8.5%
Results from 2011 (based on 2010 data)
Complaint Rate -
Customer
Lowest 10% 2,3%
Top Performer 0,5%
Average Sample 1,6%
Yield
Lowest 10% 94,5%
Top Performer 99,0%
Average Sample 96,6%
Rejected Batches
Lowest 10% 2,60%
Top Performer 0,05%
Average Sample 0,93%
35,3%
QA&QC/direct
Employees
Lowest 10% 30,6%
Top Performer 8,5%
Average Sample
Quality Cost
(direct Empl.) [in €]
Lowest 10% 16.030
Top Performer 18.871
Average Sample 24.456
Deviations
Lowest 10% 84,5
Top Performer 10,0
Average Sample 28,8
Source: Mastering Plant Complexity and the Impact of Operational Excellence, Prof. Dr. Thomas Friedli,  University of St.Gallen, OPEX-Benchmarking
Acknowledgement
Special thanks to
Dr. Thomas Friedli
who generously
shared his June
2012 presentation
Vol 32, Number 4
Jul / Aug 2012
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Unlocking the Knowledge
Unlocking the tacit knowledge
within our organisations will be one of the
significant factors to successful
implementation
of effective and efficient
Pharmaceutical Quality Systems
Knowledge Creation- Ikujiro Nonaka
“Knowledge is dynamic, since it is
created in social interactions amongst
individuals and organisations”
“Without real exchange, you can’t
create knowledge. Knowledge creation
is a human activity.”
“Tacit knowledge is a key
component of innovation”
Source : SECI, Ba and Leadership: a Unified Model of Dynamic Knowledge Creation Ikujiro Nonaka, Ryoko Toyama and Noboru Konno, Long Range
Planning 33 (2000) 5±34
Data to Wisdom -DIKW Model
Fourth Generation R&D: Managing Knowledge, Technology and Innovation, W.L. Miller and L. Morris, John
Wiley & Sons, 1999. p 87.
Path Forward for Implementation
The Challenge
How can we build
Knowledge Networks
utilising familiar OPEX, Lean/ Six
Sigma tools to capture key
Tacit Knowledge
and manage the delivery of
Process Wisdom
to enhance
Quality Decision Making
meeting the expectations and
opportunities of ICH Q10 ?
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Currently Developing a Pharma
Lean Six Sigma Toolset Go Raibh Maith Agat
Thank You
Some extra bits!
24
Deming’s System of Profound Knowledge
Deming advocated that all managers need to have
what he called a System of Profound Knowledge,
consisting of four parts:
• Appreciation of a system: understanding the
overall processes involving suppliers, producers,
and customers (or recipients) of goods and
services
• Knowledge of variation: understanding the
range and causes of variation in quality
• Theory of knowledge: the concepts explaining
knowledge and the limits of what can be known
• Knowledge of psychology: understanding the
concepts of human nature.
Source: ISPE C&Q Seminar June 2008 Washington- Good Engineering Practice, Nuala Calnan
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Deming's 14 key principles for
transforming business effectiveness
from Out of the Crisis (1992)
1. Create constancy of purpose toward
improvement.
2. Adopt the new philosophy and take
on leadership for change.
3. Cease dependence on inspection to
achieve quality by building quality
into the product in the first place.
4. End the practice of awarding business
on the basis of price tag.
5. Improve constantly and thus
constantly decrease cost
6. Institute training on the job.
7. Institute leadership.
8. Drive out fear
9. Break down barriers between
departments
10. Eliminate slogans, as the bulk of the
causes of low quality belong to the
system and not the work force.
11. a. Eliminate work standards (quotas).
Substitute leadership.
b. Eliminate management by objective.
Substitute leadership.
12. a. Remove barriers that rob the worker
of his right to pride of workmanship.
b. Remove barriers that rob people in
management and in engineering of their
right to pride of workmanship.
13. Institute a vigorous program of
education and self-improvement.
14. Put everybody in the company to work
to accomplish the transformation. The
transformation is everybody's work.
25
Source: ISPE C&Q Seminar June 2008 Washington- Good Engineering Practice, Nuala Calnan
Some Useful References
• O’Donnell, K., Strategies for Addressing the Problems of Subjectivity and
Uncertainty in Quality Risk Management Exercises: Part I — The Role of
Human Heuristics, Journal of Validation Technology, Vol. 16, No. 3,
Summer 2010
• O’Donnell, K., Strategies for Addressing the Problems of Subjectivity and
Uncertainty in Quality Risk Management Exercises: Part II — Risk
Communication and Perception, Journal of Validation Technology, Vol. 16,
No. 4, Autumn 2010
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